Anti-IL6 Receptor Antibody Treats Rheumatoid Arthritis
Summary
USPTO published patent application US20260108601A1 on April 23, 2026, filed September 22, 2025, covering methods of treating rheumatoid arthritis using an anti-IL6 receptor antibody in subjects with specific serum biomarker concentrations. The application names Anita Boyapati, Jérôme Msihid, and Moshe E. Zilberstein as inventors. Pharmaceutical and biotechnology companies developing IL-6 targeted therapies for autoimmune conditions may wish to monitor this application's prosecution for potential freedom-to-operate considerations.
“The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108601A1 on April 23, 2026, disclosing a method of treating rheumatoid arthritis using an anti-IL6 receptor antibody in subjects exhibiting certain serum biomarker concentrations. The application, filed September 22, 2025 under Application No. 19336021, names three inventors and covers antibody compositions and treatment protocols.
Pharmaceutical and biotechnology companies engaged in IL-6 pathway drug development, particularly for autoimmune indications, should monitor this application's prosecution status. Competitors developing similar IL-6R targeted biologics may face freedom-to-operate considerations if this application proceeds to grant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD OF DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS
Application US20260108601A1 Kind: A1 Apr 23, 2026
Inventors
Anita Boyapati, Jérôme Msihid, Moshe E. Zilberstein
Abstract
The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.
CPC Classifications
A61K 39/3955 A61B 5/4848 A61K 9/08 A61K 31/519 A61P 19/02 C07K 16/2866 C07K 2317/51 C07K 2317/515
Filing Date
2025-09-22
Application No.
19336021
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.